Vanda Pharmaceuticals Inc. (VNDA) – What Are Investment Firms Saying About This Stock?

Shares of Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) have been given an average recommendation of “Hold” by the nine analysts that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The average 1 year target price among analysts that have issued a report on the stock in the last year is $13.08.

A number of analysts have issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Vanda Pharmaceuticals in a report on Thursday, October 15th. Zacks Research lowered shares of Vanda Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Tuesday, October 6th. Oppenheimer started coverage on Vanda Pharmaceuticals in a research note on Wednesday, September 23rd. They set an “outperform” rating and a $10.00 price target on the stock. B. Riley Financial reaffirmed a “buy” rating and issued a $12.00 price target (down from $17.00) on shares of Vanda Pharmaceuticals in a report on Monday, August 10th. Finally, HC Wainwright reiterated a “buy” rating and issued a $20.00 price objective on shares of Vanda Pharmaceuticals in a research report on Monday, October 5th.

Vanda Pharmaceuticals Stock Performance

VNDA stock opened at $3.94 on Tuesday. The firm has a 50 day moving average of $4.91 and a two-hundred day moving average of $6.29. Vanda Pharmaceuticals has a 12 month low of $3.88 and a 12 month high of $9.94. The company has a market capitalization of $238.21 million, a price-to-earnings ratio of -0.85 and a beta of 0.69. The company has a quick ratio of 1.60, a current ratio of 1.61 and a debt-to-equity ratio of 0.01.

Vanda Pharmaceuticals (NASDAQ:VNDA) last issued its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.58) by ($0.46). The company had revenue of $50.53 million for the quarter, compared to analyst estimates of $61.92 million. Vanda Pharmaceuticals had a negative net margin of 127.41% and a negative return on equity of 49.81%. As a group, equities analysts anticipate that Vanda Pharmaceuticals will post -3.02 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Quantbot Technologies LP bought a new position in Vanda Pharmaceuticals in the second quarter worth $29,000. Legal & General Group Plc acquired a new stake in Vanda Pharmaceuticals during the second quarter worth $34,000. Allworth Financial LP acquired a new stake in Vanda Pharmaceuticals during the second quarter worth $43,000. Walleye Capital LLC acquired a new stake in Vanda Pharmaceuticals during the second quarter worth $76,000. Finally, The Manufacturers Life Insurance Company bought a new stake in Vanda Pharmaceuticals in the 2nd quarter valued at $93,000. 88.14% of the stock is currently owned by institutional investors and hedge funds.

Vanda Pharmaceuticals Company Profile

Vanda Pharmaceuticals Inc is a biopharmaceutical company focused on developing and commercializing therapies for central nervous system disorders and other conditions with significant unmet medical needs. Founded in 2003 and headquartered in Washington, DC, the company primarily serves patients and healthcare providers in the United States, with certain products and commercial rights extending to international markets.

Vanda’s marketed products include Hetlioz (tasimelteon), a treatment for Non-24-Hour Sleep-Wake Disorder in totally blind individuals and nighttime sleep disturbances associated with Smith-Magenis syndrome.